Nuveen LLC Grows Stake in AbbVie Inc. $ABBV

Nuveen LLC lifted its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 6.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 8,608,026 shares of the company’s stock after acquiring an additional 524,495 shares during the quarter. AbbVie accounts for about 0.5% of Nuveen LLC’s investment portfolio, making the stock its 21st biggest position. Nuveen LLC’s holdings in AbbVie were worth $1,966,848,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Brighton Jones LLC boosted its position in shares of AbbVie by 17.4% during the fourth quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock worth $4,072,000 after buying an additional 3,401 shares during the period. Revolve Wealth Partners LLC lifted its position in shares of AbbVie by 72.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock valued at $1,294,000 after acquiring an additional 3,064 shares during the last quarter. Schnieders Capital Management LLC. lifted its position in shares of AbbVie by 5.0% during the 2nd quarter. Schnieders Capital Management LLC. now owns 16,466 shares of the company’s stock valued at $3,056,000 after acquiring an additional 789 shares during the last quarter. Ieq Capital LLC lifted its position in shares of AbbVie by 4.6% during the 2nd quarter. Ieq Capital LLC now owns 120,035 shares of the company’s stock valued at $22,281,000 after acquiring an additional 5,274 shares during the last quarter. Finally, Worldquant Millennium Advisors LLC raised its stake in AbbVie by 117.3% during the 2nd quarter. Worldquant Millennium Advisors LLC now owns 1,135,034 shares of the company’s stock valued at $210,685,000 after purchasing an additional 612,702 shares during the period. 70.23% of the stock is owned by institutional investors.

AbbVie Price Performance

Shares of AbbVie stock opened at $225.04 on Friday. The firm has a market cap of $397.60 billion, a P/E ratio of 110.86, a P/E/G ratio of 0.69 and a beta of 0.32. The firm has a 50 day simple moving average of $210.80 and a 200 day simple moving average of $219.01. AbbVie Inc. has a fifty-two week low of $181.73 and a fifty-two week high of $244.81.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.59 by $0.06. The firm had revenue of $15 billion for the quarter, compared to analysts’ expectations of $14.72 billion. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The business’s revenue for the quarter was up 12.4% on a year-over-year basis. During the same period last year, the firm earned $2.46 earnings per share. On average, sell-side analysts expect that AbbVie Inc. will post 14.3 EPS for the current year.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Analysts and media coverage highlighted AbbVie’s Skyrizi and Rinvoq as key growth drivers, noting strong first-quarter performance and the potential for continued sales momentum through 2026, including additional indications. Will Skyrizi & Rinvoq Continue to Drive AbbVie’s Topline Through 2026?
• Positive Sentiment: Another market commentary framed AbbVie as a growth-pharma stock at a value-pharma price, reinforcing the view that its earnings growth and pipeline may justify the valuation. AbbVie: Growth-Pharma Profile At A Value-Pharma Price
• Positive Sentiment: AbbVie was also featured on CNBC’s “Final Trades”, which can support investor sentiment by keeping the stock in the market spotlight. AbbVie, Devon Energy and more on CNBC’s ‘Final Trades’
• Neutral Sentiment: Several pieces described AbbVie as a stock worth watching or holding after a strong run, with valuation and balance-sheet concerns tempering enthusiasm but not signaling a major change in the business outlook. Up 45% Since 2024: 1 Glaring Reality That Makes AbbVie Stock a Hold at $225
• Negative Sentiment: AbbVie also faced a FDA Complete Response Letter for its fast-acting neurotoxin TrenibotE, citing manufacturing-related issues. While the letter reportedly raised no safety or efficacy concerns, it delays the program and adds near-term regulatory uncertainty. FDA Issues Complete Response Letter for AbbVie’s Fast-Acting Neurotoxin TrenibotE; Spokane dermatologist Dr. Philip Werschler on What the Letter Means

Analysts Set New Price Targets

A number of research firms have recently weighed in on ABBV. Evercore set a $235.00 price target on shares of AbbVie in a research note on Friday, May 15th. Royal Bank Of Canada started coverage on shares of AbbVie in a report on Tuesday, February 24th. They issued an “outperform” rating and a $260.00 price objective for the company. Bank of America upgraded shares of AbbVie from a “neutral” rating to a “buy” rating and set a $234.00 price target for the company in a report on Thursday, April 30th. Cantor Fitzgerald restated an “overweight” rating and set a $240.00 price target on shares of AbbVie in a report on Thursday, April 30th. Finally, Piper Sandler increased their target price on shares of AbbVie from $294.00 to $298.00 and gave the company an “overweight” rating in a research note on Thursday, May 14th. Three analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $253.43.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.